Topical glaucoma therapy cost in Mexico
Autor: | Gabriel Lazcano-Gomez, Alejandra Hernandez-Oteyza, María José Iriarte-Barbosa, Carlos Hernandez-Garciadiego |
---|---|
Rok vydání: | 2013 |
Předmět: |
medicine.medical_specialty
genetic structures Administration Topical Adrenergic beta-Antagonists Brinzolamide Glaucoma Timolol Drug Costs chemistry.chemical_compound Dorzolamide Ophthalmology medicine Humans Latanoprost Carbonic Anhydrase Inhibitors Mexico Antihypertensive Agents Bimatoprost business.industry Brimonidine medicine.disease Prostaglandin analog chemistry Prostaglandins Drug Therapy Combination Ophthalmic Solutions business medicine.drug |
Zdroj: | International Ophthalmology. 34:241-249 |
ISSN: | 1573-2630 0165-5701 |
DOI: | 10.1007/s10792-013-9823-6 |
Popis: | Glaucoma is an important cause of irreversible blindness that represents a significant economic burden; most direct costs of glaucoma are drug-related. We calculated the annual cost of some of the most commonly prescribed glaucoma medications in Mexico, according to their average wholesale price (AWP) and dose regimen. Annual costs ranged from USD4.97 for Imot 15 ml (timolol 0.5 %; Laboratorios Sophia) to USD675.39 for Alphagan 5 ml (brimonidine 0.2 %; Allergan, Inc.). β-Blockers were the least expensive glaucoma medications (range USD20.44-55.44). Alphagan 5 ml was 250 % more expensive than other selective α(2)-agonists. Of the carbonic anhydrase inhibitors, dorzolamide 2 % was less expensive than brinzolamide 1 % (USD326.91 vs. USD418.96). The annual cost for prostaglandin analogs ranged from USD235.58 for bimatoprost 0.03 % to USD337.78 for latanoprost 0.005 %. Some fixed combinations were less expensive than separate combinations. The average annual cost for all treatments increased by 27.87 ± 10.09 % between 2009 and 2012. Annual glaucoma therapy cost seems to be lower in Mexico than in other countries, due to a lower AWP, especially for some medications made by Mexican laboratories. |
Databáze: | OpenAIRE |
Externí odkaz: |